News | March 13, 2024
Nirma acquires majority stake in Glenmark Life Sciences
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The company has reported total income of Rs. 547.33 crores during the period ended December 31, 2022
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)